Drug Profile
HS 10241
Alternative Names: HS-10241Latest Information Update: 17 Nov 2023
Price :
$50
*
At a glance
- Originator Jiangsu Hengrui Medicine Co.
- Class Antineoplastics
- Mechanism of Action Proto-oncogene protein c-met inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Non-small cell lung cancer
- No development reported Solid tumours
Most Recent Events
- 01 Nov 2023 Jiangsu Hansoh Pharmaceutical plans a phase III trial for Non-small cell lung cancer (Combination therapy, Second-line therapy or greater, Metastatic disease, Late-stage disease) (PO) in December 2023 (NCT06110663)
- 02 Jun 2023 Efficacy, adverse events and pharmacokinetics data from a phase Ib trial in Non-small cell lung cancer presented at 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
- 28 Jul 2022 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease) in China (PO, Tablet)